What is Medi-Tate?
Medi-Tate is dedicated to enhancing men's quality of life through effective, non-surgical treatments for Benign Prostatic Hyperplasia (BPH). Its flagship product, the iTind treatment, has achieved significant regulatory milestones, including the EU CE Mark for sale across the European Union, the UK, Israel, Australia, and Brazil. Furthermore, the iTind has received FDA clearance for use in the United States, positioning Medi-Tate as a key player in the global urology market.
How much funding has Medi-Tate raised?
Medi-Tate has raised a total of $2M across 1 funding round:
Private Equity
$2M
Private Equity (2015): $2M with participation from Xenia Venture Capital
Key Investors in Medi-Tate
Xenia Venture Capital
Xenia Venture Capital is an Israeli investment firm specializing in high-tech and med-tech sectors, with a focus on life sciences. They actively support portfolio companies through mentoring, strategic guidance, and fundraising assistance.
What's next for Medi-Tate?
With substantial backing and a product portfolio that addresses a widespread medical need, Medi-Tate is poised for significant expansion. The recent capital infusion is expected to fuel further research and development, enhance manufacturing capabilities, and accelerate market penetration in key international territories. The company's focus on non-surgical BPH solutions aligns with a growing trend towards less invasive medical interventions, suggesting a strong trajectory for future growth and market leadership.
See full Medi-Tate company page
